Patents by Inventor Stuart J. Heminway

Stuart J. Heminway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6800273
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Pharmaceuticals for the imaging of angiogenic disorders
    Publication number: 20030180305
    Abstract: The present invention describes novel compounds of the formula:
    Type: Application
    Filed: January 14, 2003
    Publication date: September 25, 2003
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6537520
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: March 25, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh